id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-D-0691-0013,FDA,FDA-2021-D-0691,Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 or Programmed Cell Death-Ligand 1 Blocking Antibodies for Treatment of Patients With Cancer; Guidance for Industry; Availability,Notice,Notice of Availability,2022-12-06T05:00:00Z,2022,12,2022-12-06T05:00:00Z,,2022-12-06T13:06:58Z,2022-26464,0,0,090000648551cdc8
FDA-2021-D-0691-0014,FDA,FDA-2021-D-0691,"Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) Blocking Antibodies for Treatment of Patients with Cancer
Guidance for Industry - Final Guidance",Other,Guidance,2022-12-06T05:00:00Z,2022,12,2022-12-06T05:00:00Z,,2024-11-07T00:44:34Z,,1,0,090000648550fc17
FDA-2021-D-0691-0001,FDA,FDA-2021-D-0691,Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 or Programmed Cell DeathLigand 1 Blocking Antibodies for Treatment of Patients With Cancer; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2021-08-26T04:00:00Z,2021,8,2021-08-26T04:00:00Z,2021-10-26T03:59:59Z,2021-10-26T01:00:33Z,2021-18317,0,0,0900006484ca8bc7
FDA-2021-D-0691-0002,FDA,FDA-2021-D-0691,"Pharmacokinetic-Based Criteria for  Supporting Alternative Dosing  Regimens of Programmed Cell  Death Receptor-1 (PD-1) or  Programmed Cell Death-Ligand 1 
(PD-L1) Blocking Antibodies for  Treatment of Patients with Cancer Guidance for Industry DRAFT GUIDANCE",Other,Guidance,2021-08-26T04:00:00Z,2021,8,2021-08-26T04:00:00Z,,2022-12-02T13:26:12Z,,0,0,0900006484ca880e